Literature DB >> 19536384

Relationship of admission hematological indexes with myocardial reperfusion abnormalities in acute ST segment elevation myocardial infarction patients treated with primary percutaneous coronary interventions.

Orhan Maden1, Fehmi Kacmaz, Hatice Selcuk, Mehmet T Selcuk, Tolga Aksu, Omac Tufekcioglu, Emir K Senen, Yucel Balbay, Erdogan Ilkay.   

Abstract

BACKGROUND: Elevated values of mean platelet volume (MPV) and elevated white blood cell (WBC) count are predictors of an unfavourable outcome among survivors of ST segment elevation myocardial infarction (STEMI). However, their relationship with reperfusion abnormalities is less clear.
OBJECTIVE: To evaluate the value of admission MPV and WBC count in predicting impaired reperfusion in patients with acute STEMI who are treated with primary percutaneous coronary intervention (PCI).
METHODS: Blood samples were obtained on admission from 368 STEMI patients who underwent successful PCI. According to the 60th minute ST segment resolution ratio, patients were divided into impaired reperfusion and reperfusion groups.
RESULTS: Impaired reperfusion was detected in 40% of study patients. Patients in the impaired reperfusion group had a higher admission MPV (9.8+/-1.3 fL versus 8.6+/-1.0 fL; P<0.001) and a higher WBC count (14.4+/-5.5 x 10(9)/L versus 12.1+/-3.8 x 10(9)/L; P<0.001) compared with the patients in the reperfusion group. In regression analysis, MPV (OR 2.21, 95% CI 1.69 to 2.91; P<0.001) and WBC count (OR 1.08, 95% CI 1.02 to 1.15; P=0.01) were found to be independently associated with impaired reperfusion. The best cut-off value of MPV for predicting impaired reperfusion was determined to be 9.05 fL, with a sensitivity of 74% and a specificity of 73%.
CONCLUSIONS: The results indicate that leukocytes and platelets have a role in the mediation of reperfusion injury. In patients with STEMI who are undergoing PCI, admission MPV may be valuable in discriminating a higher-risk patient subgroup and thus, may help in deciding the need for adjunctive therapy to improve the outcome.

Entities:  

Mesh:

Year:  2009        PMID: 19536384      PMCID: PMC2722486          DOI: 10.1016/s0828-282x(09)70090-x

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  30 in total

1.  Association of haematological indices with the degree of microvascular injury in patients with acute anterior wall myocardial infarction treated with primary percutaneous coronary intervention.

Authors:  Murat Sezer; Irem Okcular; Taner Goren; Huseyin Oflaz; Yilmaz Nisanci; Berrin Umman; Fehmi Mercanoglu; Ahmet K Bilge; Mehmet Meric; Sabahattin Umman
Journal:  Heart       Date:  2006-08-29       Impact factor: 5.994

2.  Lack of myocardial perfusion immediately after successful thrombolysis. A predictor of poor recovery of left ventricular function in anterior myocardial infarction.

Authors:  H Ito; T Tomooka; N Sakai; H Yu; Y Higashino; K Fujii; T Masuyama; A Kitabatake; T Minamino
Journal:  Circulation       Date:  1992-05       Impact factor: 29.690

Review 3.  Modulation of leukocyte-mediated myocardial reperfusion injury.

Authors:  B R Lucchesi
Journal:  Annu Rev Physiol       Date:  1990       Impact factor: 19.318

4.  Local platelet activation causes vasoconstriction of large epicardial canine coronary arteries in vivo. Thromboxane A2 and serotonin are possible mediators.

Authors:  P Golino; J H Ashton; L M Buja; M Rosolowsky; A L Taylor; J McNatt; W B Campbell; J T Willerson
Journal:  Circulation       Date:  1989-01       Impact factor: 29.690

5.  Influence of platelet size on outcome after myocardial infarction.

Authors:  J F Martin; P M Bath; M L Burr
Journal:  Lancet       Date:  1991-12-07       Impact factor: 79.321

6.  Heterogeneity of human whole blood platelet subpopulations. I. Relationship between buoyant density, cell volume, and ultrastructure.

Authors:  L Corash; H Tan; H R Gralnick
Journal:  Blood       Date:  1977-01       Impact factor: 22.113

7.  Platelet size and age determine platelet function independently.

Authors:  C B Thompson; J A Jakubowski; P G Quinn; D Deykin; C R Valeri
Journal:  Blood       Date:  1984-06       Impact factor: 22.113

8.  Activation of human platelets by C5a-stimulated neutrophils: a role for cathepsin G.

Authors:  P Ferrer-Lopez; P Renesto; M Schattner; S Bassot; P Laurent; M Chignard
Journal:  Am J Physiol       Date:  1990-06

9.  Cardiopulmonary bypass induces leukocyte-platelet adhesion.

Authors:  C S Rinder; J L Bonan; H M Rinder; J Mathew; R Hines; B R Smith
Journal:  Blood       Date:  1992-03-01       Impact factor: 22.113

10.  Influx of neutrophils into the walls of large epicardial coronary arteries in response to ischemia/reperfusion.

Authors:  R A Kloner; F Giacomelli; K J Alker; S L Hale; R Matthews; S Bellows
Journal:  Circulation       Date:  1991-10       Impact factor: 29.690

View more
  11 in total

1.  Mean platelet volume in patients with acute coronary syndromes: a supportive diagnostic predictor.

Authors:  Randheer Pal; Rajeev Bagarhatta; Sandhya Gulati; Monika Rathore; Nidhi Sharma
Journal:  J Clin Diagn Res       Date:  2014-08-20

2.  Predictors of preinterventional patency of infarct-related artery in patients with ST-segment elevation myocardial infarction: Importance of neutrophil to lymphocyte ratio and uric acid level.

Authors:  Durmuş Yıldıray Sahin; Mustafa Gür; Zafer Elbasan; Ali Yıldız; Zekeriya Kaya; Yahya Kemal Içen; Ali Kıvrak; Caner Türkoğlu; Remzi Yılmaz; Murat Caylı
Journal:  Exp Clin Cardiol       Date:  2013

3.  Relationship of admission mean platelet volume, platelet distribution width and white blood cells with ST resolution in patients with acute ST segment elevation myocardial infarction treated with streptokinase without history of previous cardiovascular surgery.

Authors:  H R Varasteh-Ravan; Sadeq Ali-Hasan-Al-Saegh; Shohre Shokraneh; Mohammad R Mozayan; Ali Akbar Karimi-Bondarabadi
Journal:  Perspect Clin Res       Date:  2013-04

4.  A brief review of biomarkers for preventing and treating cardiovascular diseases.

Authors:  Xiaolun Sun; Zhenquan Jia
Journal:  J Cardiovasc Dis Res       Date:  2012-10

5.  Influence of pre-existing inflammation on the outcome of acute coronary syndrome: a cross-sectional study.

Authors:  Jacob Odeberg; Michael Freitag; Henrik Forssell; Ivar Vaara; Marie-Louise Persson; Håkan Odeberg; Anders Halling; Lennart Råstam; Ulf Lindblad
Journal:  BMJ Open       Date:  2016-01-12       Impact factor: 2.692

Review 6.  Mean platelet volume: a potential biomarker of the risk and prognosis of heart disease.

Authors:  Dong-Hyun Choi; Seong-Ho Kang; Heesang Song
Journal:  Korean J Intern Med       Date:  2016-10-24       Impact factor: 2.884

7.  Usefulness of white blood cell count to mean platelet volume ratio in the prediction of SYNTAX score in patients with non-ST elevation myocardial infarction.

Authors:  Serkan Sivri; Erdogan Sokmen; Mustafa Celik; Sinan Cemgil Ozbek; Alp Yildirim; Yalcin Boduroglu
Journal:  Pak J Med Sci       Date:  2019       Impact factor: 1.088

8.  Mean Platelet Volume as a Potential Marker of Large Vessel Occlusion and Predictor of Outcome in Acute Ischemic Stroke Patients Treated with Reperfusion Therapy.

Authors:  Aleksander Dębiec; Aleksandra Pogoda-Wesołowska; Piotr Piasecki; Adam Stępień; Jacek Staszewski
Journal:  Life (Basel)       Date:  2021-05-24

9.  White Blood Cell Counts to High-Density Lipoprotein Cholesterol Ratio, as a Novel Predictor of Long-Term Adverse Outcomes in Patients After Percutaneous Coronary Intervention: A Retrospective Cohort Study.

Authors:  Ting-Ting Wu; Ying-Ying Zheng; Wen-Juan Xiu; Wan-Rong Wang; Yi-Li Xun; Yan-Yan Ma; Patigvl Kadir; Ying Pan; Yi-Tong Ma; Xiang Xie
Journal:  Front Cardiovasc Med       Date:  2021-07-08

10.  The utility of inflammation and platelet biomarkers in patients with acute coronary syndromes.

Authors:  Joanna Kamińska; Olga M Koper; Edyta Siedlecka-Czykier; Joanna Matowicka-Karna; Jerzy Bychowski; Halina Kemona
Journal:  Saudi J Biol Sci       Date:  2016-10-24       Impact factor: 4.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.